Masimo (NASDAQ:MASI) Stock Price Up 3.4%

Masimo Co. (NASDAQ:MASIGet Free Report) shares rose 3.4% during trading on Monday . The company traded as high as $132.09 and last traded at $131.60. Approximately 146,417 shares were traded during trading, a decline of 77% from the average daily volume of 647,676 shares. The stock had previously closed at $127.28.

Analysts Set New Price Targets

MASI has been the topic of a number of analyst reports. StockNews.com cut Masimo from a “hold” rating to a “sell” rating in a research note on Thursday, November 16th. Wells Fargo & Company cut their target price on Masimo from $110.00 to $81.00 and set an “equal weight” rating on the stock in a research note on Wednesday, November 8th. Raymond James cut Masimo from an “outperform” rating to a “market perform” rating in a research note on Wednesday, November 8th. Needham & Company LLC cut Masimo from a “buy” rating to a “hold” rating in a research note on Wednesday, January 3rd. Finally, Jefferies Financial Group reaffirmed a “hold” rating and set a $121.00 target price (up previously from $107.00) on shares of Masimo in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, Masimo has an average rating of “Hold” and an average target price of $121.86.

Get Our Latest Research Report on Masimo

Masimo Stock Performance

The company has a market cap of $6.81 billion, a P/E ratio of 78.63 and a beta of 1.00. The firm has a 50 day moving average of $112.54 and a 200-day moving average of $104.05. The company has a quick ratio of 1.13, a current ratio of 2.14 and a debt-to-equity ratio of 0.71.

Masimo (NASDAQ:MASIGet Free Report) last announced its quarterly earnings data on Tuesday, November 7th. The medical equipment provider reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.04. Masimo had a return on equity of 14.18% and a net margin of 4.19%. The company had revenue of $478.90 million for the quarter, compared to analysts’ expectations of $498.73 million. During the same quarter in the prior year, the firm earned $1.00 earnings per share. Masimo’s revenue was down 12.8% compared to the same quarter last year. As a group, sell-side analysts anticipate that Masimo Co. will post 3.49 EPS for the current fiscal year.

Institutional Trading of Masimo

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. boosted its position in Masimo by 3.0% during the 2nd quarter. BlackRock Inc. now owns 6,120,123 shares of the medical equipment provider’s stock valued at $1,007,066,000 after acquiring an additional 178,267 shares in the last quarter. Vanguard Group Inc. boosted its position in Masimo by 1.5% during the 1st quarter. Vanguard Group Inc. now owns 4,775,660 shares of the medical equipment provider’s stock valued at $695,050,000 after acquiring an additional 71,918 shares in the last quarter. State Street Corp lifted its holdings in shares of Masimo by 1.6% during the 1st quarter. State Street Corp now owns 1,730,991 shares of the medical equipment provider’s stock valued at $251,928,000 after purchasing an additional 27,261 shares during the last quarter. Massachusetts Financial Services Co. MA purchased a new stake in shares of Masimo during the 3rd quarter valued at $132,699,000. Finally, Eminence Capital LP purchased a new stake in shares of Masimo during the 3rd quarter valued at $90,859,000. Institutional investors own 85.96% of the company’s stock.

About Masimo

(Get Free Report)

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and O3 regional oximetry.

Read More

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.